| Drug General Information |
| Drug ID |
D07BLJ
|
| Former ID |
DNC004416
|
| Drug Name |
[1,5]Thiazocan-(4E)-ylideneamine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C6H12N2S
|
| Canonical SMILES |
C1CN=C(CCSC1)N
|
| InChI |
1S/C6H12N2S/c7-6-2-5-9-4-1-3-8-6/h1-5H2,(H2,7,8)
|
| InChIKey |
CMKCQRINBMEZKA-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Nitric oxide synthase, inducible |
Target Info |
Inhibitor |
[1]
|
|---|
|
BioCyc Pathway
|
Citrulline-nitric oxide cycle
|
|
KEGG Pathway
|
Arginine biosynthesis
|
|
Arginine and proline metabolism
|
|
Metabolic pathways
|
|
Calcium signaling pathway
|
|
HIF-1 signaling pathway
|
|
Peroxisome
|
|
Salmonella infection
|
|
Pertussis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Amoebiasis
|
|
Tuberculosis
|
|
Pathways in cancer
|
|
Small cell lung cancer
|
|
NetPath Pathway
|
IL1 Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
Pathway Interaction Database
|
IL12-mediated signaling events
|
|
Alpha9 beta1 integrin signaling events
|
|
ATF-2 transcription factor network
|
|
IL23-mediated signaling events
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
HIF-1-alpha transcription factor network
|
|
Reactome
|
ROS production in response to bacteria
|
|
Nitric oxide stimulates guanylate cyclase
|
|
WikiPathways
|
Type II interferon signaling (IFNG)
|
|
Spinal Cord Injury
|
|
AGE/RAGE pathway
|
|
Effects of Nitric Oxide
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. |
|---|
